Genetic drug target validation using Mendelian randomisation.
Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, Tyl B, Chopade S, Faraway R, Zwierzyna M, Hingorani AD. · 2020
Read Genetic drug target validation using Mendelian randomisation. by Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, Tyl B, Chopade S, Faraway R, Zwierzyna M, Hingorani AD. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7320010.txt.
Description
Schmidt and co-authors sharpen a genetic method, Mendelian randomisation, for judging whether a protein is a good drug target. Their paper appeared in Nature Communications. The method uses genetic variants as natural instruments to test whether a risk factor truly causes disease. Its weak spot is horizontal pleiotropy, where a variant influences disease through a second, unrelated pathway.
When the risk factor is a protein, that worry shrinks. Proteins are the direct products of genes and the proximal effectors of biology, and most medicines target proteins. The authors build a mathematical framework contrasting protein targets with risk factors further down the causal chain. It guides key model decisions, boosts statistical power, and tests how robust a target-validation result really is before money is spent on drug development.
Catalog record
| CREATOR | Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, Tyl B, Chopade S, Faraway R, Zwierzyna M, Hingorani AD. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 74 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |